



PRESS RELEASE

February 5, 2024

Ziccum CEO video interview: mRNA in focus

In an interview in Swedish, Ziccum CEO Ann Gidner discusses the company's new in vivo mRNA data, the mRNA market potential and technology and how Ziccum's LaminaPace can solve crucial stability and delivery challenges that can help unlock the full potential of the platform. The interview is carried out by Eucaps analyst Jonathan Furelid.

Watch the interview, in Swedish, here. <https://www.youtube.com/watch?v=fRbzBKhwCSY>

For more information about Ziccum, please contact:

Ann Gidner,
CEO Ziccum
Mail: gidner@ziccum.com
Mobile: +46 722140141

Fredrik Sjövall,
Chairman of the Board, Ziccum AB
Mail: sjovall@ziccum.com
Mobile: +46 706 45 08 75

Ziccum's Certified Adviser is
Carnegie Investment Bank AB (publ).
Follow us on <https://eucaps.com/ziccum>

About Ziccum

Ziccum is developing LaminaPace™, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminaPace™ uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Attachments

[Ziccum CEO video interview: mRNA in focus](#)